Elotuzumab

DB06317

biotech approved

Deskripsi

Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) The clearance of elotuzumab decreased from a geometric mean (CV%) of 17.5 (21.2%) to 5.8 (31%) mL/day/kg with an increase in dose from 0.5 (i.e., 0.05 times the recommended dosage) to 20 mg/kg (i.e., 2 times the recommended dosage). Based on a population PK model, when elotuzumab is given in combination with lenalidomide and dexamethasone, approximately 97% of the maximum steady-state concentration is predicted to be eliminated with a geometric mean (CV%) of 82.4 (48%) days.

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Elotuzumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Elotuzumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Elotuzumab.
Estrone Estrone may increase the thrombogenic activities of Elotuzumab.
Estradiol Estradiol may increase the thrombogenic activities of Elotuzumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Elotuzumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Elotuzumab.
Mestranol Mestranol may increase the thrombogenic activities of Elotuzumab.
Estriol Estriol may increase the thrombogenic activities of Elotuzumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Elotuzumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Elotuzumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Elotuzumab.
Tibolone Tibolone may increase the thrombogenic activities of Elotuzumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Elotuzumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Elotuzumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Elotuzumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Elotuzumab.
Zeranol Zeranol may increase the thrombogenic activities of Elotuzumab.
Equol Equol may increase the thrombogenic activities of Elotuzumab.
Promestriene Promestriene may increase the thrombogenic activities of Elotuzumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Elotuzumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Elotuzumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Elotuzumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Elotuzumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Elotuzumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Elotuzumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Elotuzumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Elotuzumab.
Formononetin Formononetin may increase the thrombogenic activities of Elotuzumab.
Estetrol Estetrol may increase the thrombogenic activities of Elotuzumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Elotuzumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Elotuzumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Elotuzumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Elotuzumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Elotuzumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Elotuzumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Elotuzumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Elotuzumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Elotuzumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Elotuzumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Elotuzumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Elotuzumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Elotuzumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Elotuzumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Elotuzumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Elotuzumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Elotuzumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Elotuzumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Elotuzumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Elotuzumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Elotuzumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Elotuzumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Elotuzumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Elotuzumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Elotuzumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Elotuzumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Elotuzumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Elotuzumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Elotuzumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Elotuzumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Elotuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Elotuzumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Elotuzumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Elotuzumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Elotuzumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Elotuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Elotuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Elotuzumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Elotuzumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Elotuzumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Elotuzumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Elotuzumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Elotuzumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Elotuzumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Elotuzumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Elotuzumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Elotuzumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Elotuzumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Elotuzumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Elotuzumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Elotuzumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Elotuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Elotuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Elotuzumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Elotuzumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Elotuzumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Elotuzumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Elotuzumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Elotuzumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Elotuzumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Elotuzumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Elotuzumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Elotuzumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Elotuzumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Elotuzumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Elotuzumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Elotuzumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Elotuzumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Elotuzumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Elotuzumab.

Target Protein

SLAM family member 7 SLAMF7

Referensi & Sumber

Synthesis reference: "Patent Link":https://www.google.com/patents/WO2014055370A1?cl=en
Artikel (PubMed)
  • PMID: 18451245
    Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB: CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008 May 1;14(9):2775-84. doi: 10.1158/1078-0432.CCR-07-4246.
  • PMID: 17906076
    Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15;112(4):1329-37. Epub 2007 Sep 28.
  • PMID: 26809244
    Markham A: Elotuzumab: First Global Approval. Drugs. 2016 Mar;76(3):397-403. doi: 10.1007/s40265-016-0540-0.

Contoh Produk & Brand

Produk: 8 • International brands: 0
Produk
  • Elotuzumab
    Injection, powder, lyophilized, for solution • 300 mg/1 • Intravenous • US
  • Elotuzumab
    Injection, powder, lyophilized, for solution • 300 mg/1 • Intravenous • US
  • Empliciti
    Injection, powder, lyophilized, for solution • 300 mg/1 • Intravenous • US • Approved
  • Empliciti
    Injection, powder, lyophilized, for solution • 400 mg/1 • Intravenous • US • Approved
  • Empliciti
    Powder, for solution • 440 mg / vial • Intravenous • Canada • Approved
  • Empliciti
    Powder, for solution • 340 mg / vial • Intravenous • Canada • Approved
  • Empliciti
    Injection, powder, for solution • 300 mg • Intravenous • EU • Approved
  • Empliciti
    Injection, powder, for solution • 400 mg • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul